Vertex Initiates Phase 3 Studies of VX-445, Tezacaftor and Ivacaftor as a Triple Combination Regimen for People with Cystic Fibrosis

-VX-445 triple combination regimen is the second of two different triple combination regimens to enter Phase 3 development in 2018- -Phase 3 study in approximately 360 patients with one F508del mutation and one minimal function mutation designed to support New

Vertex Initiates Phase 3 Study of VX-659, Tezacaftor and Ivacaftor as a Triple Combination Regimen for People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation

-Global Phase 3 study to enroll approximately 100 patients with the most common genetic form of the disease- -Phase 2 data showed mean absolute improvement in ppFEV1 of 9.7 percentage points when VX-659 was added in people with CF who have

Vertex Announces Treatment with the NaV1.8 Inhibitor VX-150 Showed Significant Relief of Acute Pain in Phase 2 Study

-VX-150 was generally well tolerated and showed statistically significant relief of acute pain compared to placebo; study included an active reference arm of the opioid pain medicine hydrocodone+acetaminophen to support evaluation of VX-150 treatment effect- -Phase 2 study in acute

FDA Approves SYMDEKOTM (tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older with Certain Mutations in the CFTR Gene

– SYMDEKO is Vertex’s third medicine to treat the underlying cause of CF – – SYMDEKO to begin shipping to pharmacies this week – Feb 12, 2018 BOSTON–(BUSINESS WIRE)– Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA)